189 related articles for article (PubMed ID: 34773163)
1. Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Rühle A; Wiedenmann N; Fennell JT; Mix M; Ruf J; Stoian R; Thomsen AR; Vaupel P; Baltas D; Grosu AL; Nicolay NH
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1650-1660. PubMed ID: 34773163
[TBL] [Abstract][Full Text] [Related]
2. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
4. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
5. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
6. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
7. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
[TBL] [Abstract][Full Text] [Related]
8. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
9. Correlative analyses between tissue-based hypoxia biomarkers and hypoxia PET imaging in head and neck cancer patients during radiochemotherapy-results from a prospective trial.
Nicolay NH; Wiedenmann N; Mix M; Weber WA; Werner M; Grosu AL; Kayser G
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1046-1055. PubMed ID: 31811344
[TBL] [Abstract][Full Text] [Related]
10. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of quantitative imaging parameters in head and neck squamous cell carcinoma.
Gupta T; Chatterjee A; Rangarajan V; Purandare N; Arya S; Murthy V; Budrukkar A; Ghosh-Laskar S; Agarwal JP
Q J Nucl Med Mol Imaging; 2022 Jun; 66(2):162-170. PubMed ID: 31496204
[TBL] [Abstract][Full Text] [Related]
12. Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial.
Nicolay NH; Rühle A; Wiedenmann N; Niedermann G; Mix M; Weber WA; Baltas D; Werner M; Kayser G; Grosu AL
J Nucl Med; 2021 Apr; 62(4):471-478. PubMed ID: 32859699
[TBL] [Abstract][Full Text] [Related]
13. The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Ruf J; Bieber B; Stoian R; Thomsen AR; Gkika E; Vaupel P; Baltas D; Weber WA; Mix M; Nicolay NH
Clin Transl Radiat Oncol; 2022 Mar; 33():120-127. PubMed ID: 35243023
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Rühle A; Grosu AL; Wiedenmann N; Stoian R; Haehl E; Zamboglou C; Baltas D; Werner M; Kayser G; Nicolay NH
Radiother Oncol; 2021 Jun; 159():75-81. PubMed ID: 33753155
[TBL] [Abstract][Full Text] [Related]
16. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
17. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
18.
van den Bosch S; Doornaert PAH; Dijkema T; Zwijnenburg EM; Verhoef LCG; Hoeben BAW; Kasperts N; Smid EJ; Terhaard CHJ; Kaanders JHAM
Radiother Oncol; 2020 Jan; 142():107-114. PubMed ID: 31439447
[TBL] [Abstract][Full Text] [Related]
19. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
20. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
